Register or Login
  • All
  • Uniprot Id
  • Catalog #
  • Peptide Sequence
>   home   >   Products   >   Peptides   >   Blocking Peptides   >   EFHD2 Antibody (C-term) Blocking Peptide   

EFHD2 Antibody (C-term) Blocking Peptide

Synthetic peptide

Product Information
Primary Accession Q96C19
Clone Names 91113133
Additional Information
Other Names EF-hand domain-containing protein D2, Swiprosin-1, EFHD2, SWS1
Target/Specificity The synthetic peptide sequence used to generate the antibody AP9285b was selected from the C-term region of human EFHD2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
StorageMaintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Protein Information
Name EFHD2
Synonyms SWS1
Function May regulate B-cell receptor (BCR)-induced immature and primary B-cell apoptosis. Plays a role as negative regulator of the canonical NF-kappa-B-activating branch. Controls spontaneous apoptosis through the regulation of BCL2L1 abundance.
Cellular Location Membrane raft. Note=In a mouse immature B-cell line WEHI-231.
Tissue Location Found in lymphocytes; preferentially expressed in CD8+ cells. EMBL; AL031283; -; NOT_ANNOTATED_CDS; Genomic_DNA EMBL; CH471167; EAW51720.1; -; Genomic_DNA EMBL; BC007233; AAH07233.1; -; mRNA EMBL; BC014923; AAH14923.1; -; mRNA EMBL; BC023611; AAH23611.1; -; mRNA EMBL; BC068473; AAH68473.1; -; mRNA CCDS; CCDS155.1; - RefSeq; NP_077305.2; NM_024329.5 PDB; 5H0P; X-ray; 1.86 A; A=70-184 PDB; 5I2L; X-ray; 1.85 A; A=70-184 PDB; 5I2O; X-ray; 1.95 A; A=70-184 PDB; 5I2Q; X-ray; 1.94 A; A=70-184 PDBsum; 5H0P; - PDBsum; 5I2L; - PDBsum; 5I2O; - PDBsum; 5I2Q; - SMR; Q96C19; - BioGRID; 122597; 59 IntAct; Q96C19; 19 MINT; Q96C19; - STRING; 9606.ENSP00000365147; - iPTMnet; Q96C19; - MetOSite; Q96C19; - PhosphoSitePlus; Q96C19; - SwissPalm; Q96C19; - BioMuta; EFHD2; - DMDM; 20140139; - REPRODUCTION-2DPAGE; IPI00060181; - SWISS-2DPAGE; Q96C19; - EPD; Q96C19; - jPOST; Q96C19; - MassIVE; Q96C19; - MaxQB; Q96C19; - PaxDb; Q96C19; - PeptideAtlas; Q96C19; - PRIDE; Q96C19; - ProteomicsDB; 76150; - TopDownProteomics; Q96C19; - Antibodypedia; 28833; 160 antibodies Ensembl; ENST00000375980; ENSP00000365147; ENSG00000142634 GeneID; 79180; - KEGG; hsa:79180; - UCSC; uc001awh.2; human CTD; 79180; - DisGeNET; 79180; - EuPathDB; HostDB:ENSG00000142634.12; - GeneCards; EFHD2; - HGNC; HGNC:28670; EFHD2 HPA; ENSG00000142634; Low tissue specificity MIM; 616450; gene neXtProt; NX_Q96C19; - OpenTargets; ENSG00000142634; - PharmGKB; PA134942316; - eggNOG; KOG0041; Eukaryota eggNOG; ENOG4111JG9; LUCA GeneTree; ENSGT00390000012058; - HOGENOM; CLU_094429_0_0_1; - InParanoid; Q96C19; - KO; K23922; - OMA; NEGIGEH; - OrthoDB; 1511376at2759; - PhylomeDB; Q96C19; - TreeFam; TF320736; - BioGRID-ORCS; 79180; 16 hits in 787 CRISPR screens ChiTaRS; EFHD2; human GenomeRNAi; 79180; - Pharos; Q96C19; Tbio PRO; PR:Q96C19; - Proteomes; UP000005640; Chromosome 1 RNAct; Q96C19; protein Bgee; ENSG00000142634; Expressed in blood and 204 other tissues ExpressionAtlas; Q96C19; baseline and differential Genevisible; Q96C19; HS GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL GO; GO:0005509; F:calcium ion binding; IEA:InterPro CDD; cd00051; EFh; 1 InterPro; IPR011992; EF-hand-dom_pair InterPro; IPR002048; EF_hand_dom InterPro; IPR040365; EFHD1/2 PANTHER; PTHR13025; PTHR13025; 1 Pfam; PF13405; EF-hand_6; 1 SMART; SM00054; EFh; 2 SUPFAM; SSF47473; SSF47473; 1 PROSITE; PS50222; EF_HAND_2; 2 1: Evidence at protein level; 3D-structure; Acetylation; Calcium; Direct protein sequencing; Membrane; Metal-binding; Phosphoprotein; Reference proteome; Repeat INIT_MET 1 /note="Removed" /evidence="ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:22814378, ECO:0000269|Ref.4" CHAIN 2..240 /note="EF-hand domain-containing protein D2" /id="PRO_0000073645" DOMAIN 92..127 /note="EF-hand 1" /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" DOMAIN 128..163 /note="EF-hand 2" /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" CA_BIND 105..116 /note="1" /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" CA_BIND 141..152 /note="2" /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" MOD_RES 2 /note="N-acetylalanine" /evidence="ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:22814378, ECO:0000269|Ref.4" MOD_RES 11 /note="Phosphoserine" /evidence="ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163" MOD_RES 74 /note="Phosphoserine" /evidence="ECO:0000244|PubMed:16964243, ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:19690332, ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569" MOD_RES 76 /note="Phosphoserine" /evidence="ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569" MOD_RES 83 /note="Phosphotyrosine" /evidence="ECO:0000250|UniProtKB:Q9D8Y0" MOD_RES 233 /note="N6-acetyllysine" /evidence="ECO:0000244|PubMed:19608861" HELIX 82..85 /evidence="ECO:0000244|PDB:5I2L" HELIX 91..104 /evidence="ECO:0000244|PDB:5I2L" STRAND 109..112 /evidence="ECO:0000244|PDB:5I2L" HELIX 114..124 /evidence="ECO:0000244|PDB:5I2L" HELIX 130..140 /evidence="ECO:0000244|PDB:5I2L" STRAND 145..149 /evidence="ECO:0000244|PDB:5I2L" HELIX 150..161 /evidence="ECO:0000244|PDB:5I2L" HELIX 170..177 /evidence="ECO:0000244|PDB:5I2L" SEQUENCE 240 AA; 26697 MW; 9FE3FEC3007A8FC2 CRC64; MATDELATKL SRRLQMEGEG GGETPEQPGL NGAAAAAAGA PDEAAEALGS ADCELSAKLL RRADLNQGIG EPQSPSRRVF NPYTEFKEFS RKQIKDMEKM FKQYDAGRDG FIDLMELKLM MEKLGAPQTH LGLKNMIKEV DEDFDSKLSF REFLLIFRKA AAGELQEDSG LCVLARLSEI DVSSEGVKGA KSFFEAKVQA INVSSRFEEE IKAEQEERKK QAEEMKQRKA AFKELQSTFK
Research Areas
Citations (0)

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.

Submit your citation using an Abcepta antibody to, and receive a free "I Love Antibodies" mug.


EFHD2 may regulate B-cell receptor (BCR)-induced immature and primary B-cell apoptosis. EFHD2 plays a role as negative regulator of the canonical NF-kappa-B-activating branch. This protein controls spontaneous apoptosis through the regulation of BCL2L1 abundance.


Thylur,R.P.,, J. Cell. Biochem. 108 (3), 705-715 (2009)Martins-de-Souza,D.,, Eur Arch Psychiatry Clin Neurosci 259 (3), 151-163 (2009)Avramidou,A.,, Cell Death Differ. 14 (11), 1936-1947 (2007)

Abcepta welcomes feedback from its customers.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.

If you have any additional inquiries please email technical services at

$ 277.78
Cat# BP9285b
Availability: 2 weeks
Bulk Size

Ordering Information

United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
Abcepta, Inc.
(888) 735-7227 / (858) 622-0099
(858) 622-0609
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900
Cedarlane Labs
+1 (800) 721-1644
+1 (336) 513-5138

Shipping Information

Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
Terms & Conditions